GlassScriptPhysician profile
Charles A Rocci
NPI 1891735668
$1,000.01
in general payments reported to CMS, 2019-2025
15 companies · $618 in 2025
The $618 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2024: $144 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $216.72 | 2022-2024 | |
| Amgen INC. | $199.54 | 2025 | Evenity, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $109.32 | 2025 | |
| Smith+Nephew, INC. | $80.21 | 2022 | |
| Polymedics Innovations INC. | $70.60 | 2025 | |
| Mimedx Group, INC. | $54.67 | 2025 | |
| Solventum Corporation | $53.60 | 2024 | Activ.A.C., V.A.C.Ulta, 3m Coban |
| Exact Sciences Corporation | $43.33 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $42.53 | 2025 | Breztri, Airsupra |
| Sequel Med Tech, LLC | $36.90 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $22.74 | 2025 | |
| Beta Bionics, INC. | $21.82 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Innovation Technologies INC | $17.19 | 2022 | |
| Eisai INC. | $16.25 | 2025 | |
| Bioventus LLC | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rocci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.